TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021

Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.

Daniel J Olson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.